Dr. Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is ...

Q1 2025 Earnings Call Transcript May 2, 2025 Operator: Thank you for standing by. Hello and welcome to the Summit Therapeutics Q1 2025 Earnings Conference Call. I would now like to turn the call over ...

Additionally, Akeso continues to enroll multiple Phase III clinical trials, including biliary tract cancer ... patients with squamous or non-squamous histology with no activating genomic ...

The company is also stopping all studies of the drug in primary biliary cholangitis (PBC ... after CymaBay saw “atypical” findings on histology studies from liver biopsies that suggested ...

The Bismuth–Corlette classification system provides an anatomic description of the tumor location and longitudinal extension in the biliary tree (Figure 3). It is limited due to its failure to ...

Vague symptoms can be significant warnings of bile duct cancer, a relatively rare condition with about 2,200 cases annually in the UK. Unfortunately, these are often diagnosed at an advanced stage ...

The Bile Titan is Helldivers 2‘s version of “hey, what if that bug was the size of a building and also hated you personally?” This acid-spewing Terminid tank is slow but terrifying ...

Biochemical evidence of improvement after drug withdrawal is occasionally supported by a return to normal histology.

AstraZeneca’s (AZ) Imfinzi (durvalumab) has been approved in the European Union (EU) as first-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC ...